India’s API market could hit $22.18 billion by 2031: 3 pharma stocks to watch

India’s API market is estimated at US$15.28 billion in 2026, up from US$14.18 billion in 2025, and is projected to reach US$22.18 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.74%, according to Mordor Intelligence. The global API market was valued at US$270.5 billion in 2025 and is forecast to reach US$287.1 billion in 2026, according to Grand View Research. However, import dependence remains a key concern.

India imported approximately US$4.35 billion of APIs, bulk drugs, and drug intermediates in FY25, with China accounting for 73.71% of the total. This creates an opportunity for domestic manufacturers like Aurobindo Pharma, Laurus Labs, and Divi’s Laboratories to expand production and strengthen supply chains. To assess which companies could benefit, the focus shifts to three different business models: integrated API manufacturing, contract development and manufacturing, and custom synthesis.

FE Stock Insights on WhatsApPGet instant alerts on high-conviction investment themes and fundamental deep dives—direct from Financial Express.Join now #1 Aurobindo Pharma: Moving from APIs to Contracted Drug Manufacturing Aurobindo Pharma makes pharmaceutical ingredients and finished medicines. Its API operations span beta-lactam and non-beta-lactam products. Its portfolio includes penicillins, cephalosporins, antiretrovirals, and other anti-infective ingredients.

Vertical integration allows the company to supply APIs to external customers while using some ingredients in its own formulations. Through AuroSource, it also offers contract development and manufacturing services covering registered starting materials, advanced intermediates and APIs. The API Mix Reveals Where Growth Is Coming From Aurobindo's API business commercialised more than 200 APIs, supported by research, process development and analytical facilities.

Five API manufacturing facilities have historically received approvals from major regulators, including the United States Food and Drug Administration (US FDA). API revenue for the quarter ended 30 June 2026 was ₹1,049 crore, up 14.6% year on year but down 13.1% sequentially. Beta-lactam API revenue increased 25.7% year on year to ₹800 crore, while non-beta-lactam API revenue declined 10.6% to ₹250 crore.

Sequentially, beta-lactam revenue fell 12.9% and non-beta-lactam revenue declined 13.8%. APIs contributed 11.5% of consolidated revenue of ₹9,150 crore. AuroSource Adds a Different Route to Commercial Growth AuroSource covers process development, scale-up, stability studies, regulatory support and commercial manufacturing. The platform reports experience across more than 1,000 regulatory filings and over 200 commercialised products.

Customers can engage at different development stages, with exclusive manufacturing arrangements possible under mutually agreed contracts. Why 10 US FDA Approvals and a $247M Acquisition Matter for Cash Flow Aurobindo exports to more than 150 countries, with approximately 90% of revenue derived from international operations according to its business overview. The United States and Europe are its largest markets, alongside destinations such as South Africa, Brazil and Canada.

The company's Q1FY27 release listed 10 products receiving final US FDA approval, including canagliflozin, pirfenidone and cephalexin for oral suspension. These were formulation approvals, not evidence of new API launches. Capital allocation also deserves attention. During the quarter, the company made a US$247 million acquisition-related payment for Lannett and conducted a US$85 million share buyback.

As of 30 June 2026, it reported a net cash position of US$42 million, including investments, and free cash flow of US$98 million. Aurobindo Pharma’s Rally Meets a More Modest Brokerage Target Source: Screener.in; Stock Price as on 15th October 2026 Aurobindo Pharma's share price rose around 21% in the span of six months. One-year return stood at 49%. The stock has a price-to-earnings (P/E) ratio of 25.52.

Motilal Oswal maintained a Buy rating in its report dated 6 August 2026, with a target price of ₹1,860. Compared with Aurobindo’s closing price of ₹1,677.90 on the National Stock Exchange (NSE) on 15 October 2026, the target implies a potential upside of around 10.9%. Its API portfolio covers antiretroviral (ARV), oncology, cardiovascular and central nervous system (CNS) therapies, while its contract manufacturing operations support drug development and commercial production.

The business offers two distinct sources of activity: supplying ingredients for established medicines and developing molecules for customers that outsource parts of their pharmaceutical production. API Growth and CDMO Expansion Are Moving at Different Speeds Laurus generated API revenue of ₹2,746 crore in FY26, up 13% from FY25. Its small molecule CDMO business recorded revenue of ₹1,896 crore, an increase of 38% on a YoY basis.

The contrast shows that contract manufacturing grew faster than the established API business during the year, although the two activities have different customer requirements, development timelines, and demand drivers. The company reported 92 cumulative drug master file (DMF) filings by March 2026, including two additional filings during FY26. Its API portfolio spans ARVs, oncology, and other therapeutic areas, with high-potency oncology manufacturing and expansion into diabetes and ophthalmology adding to its capabilities.

The 125-Project Pipeline Is a Starting Point, Not a Revenue Projection Laurus’s small molecule CDMO pipeline surpassed 125 active projects in FY26, comprising over 102 in human health and about 23 in animal health and crop science. The company uses technologies including flow chemistry and biocatalysis across projects at different production scales, while strengthening commercial peptide manufacturing.

The pipeline is relevant because it indicates the breadth of customer development activity. Early development work and established commercial manufacturing have very different levels of revenue visibility. Capacity Expansion Raises the Stakes on Commercial Execution Laurus spent ₹1,070 crore on capital expenditure in FY26, taking cumulative capital expenditure since FY22 to more than ₹4,350 crore.

Its investments include intermediate and API manufacturing blocks at Visakhapatnam, commercial peptide facilities, fermentation capacity and advanced development infrastructure. The company also secured 531.77 acres of land in Andhra Pradesh in July 2025 for future expansion. Its FY26 annual report identified 11 ongoing growth projects, including seven API projects. These investments increase the company's ability to manufacture across different products and production scales.

New facilities must pass the relevant qualification and approval processes, attract commercial volumes and operate efficiently before their full economic value becomes visible. Laurus Labs’ Rally: Can Business Execution Catch Up With Expectations? Source: Screener.in; Stock Price as on 15th October 2026 Laurus Labs' share price rose more than 78% over six months, while its one-year return stood at 130%.

The company has a P/E ratio of 99.9. Motilal Oswal maintained a Buy rating on 24 July 2026 with a target price of ₹1,980. The stock closed at ₹2,018.50 on 15 October 2026, above the stated target price. The strong past return and high P/E suggest that investors are already assigning substantial value to the company's growth prospects. That does not establish that the stock is overvalued, but it raises the importance of execution: sustained growth, continued margin performance and successful commercialisation of CDMO projects become particularly relevant when expectations are high. #3 Divi’s Laboratories: Complex Chemistry, Global Drugmakers and Long-Term Supply Programmes Divi’s Laboratories manufactures generic APIs and intermediates and provides custom synthesis services to pharmaceutical innovators.

Its operations cover established high-volume ingredients as well as complex molecules produced for customers under development and manufacturing arrangements. The company reports 30 commercial generic APIs, including products in which it is among the world's largest manufacturers. Its custom synthesis business supports pharmaceutical programmes from development and validation through commercial production.

This creates a different investment profile from a manufacturer focused mainly on standardised ingredients: customer-specific chemistry and long-term supply arrangements can provide a route to higher-value work. Generic APIs and Intermediates: Making Established Chemistry More Efficient Divi’s generic API business relies on process efficiency, backward integration and cost control. Its products are manufactured at volumes ranging from tens to thousands of metric tonnes annually.

Pricing pressure can limit revenue growth even when volumes remain stable, making production efficiency and the cost of inputs important to the economics of established products. 86 lakh cr grid push: 2 ‘under-the-radar’ transformer stocks with 40%+ ROCE Intermediates and starting materials also have a strategic role. Producing them internally can reduce reliance on external suppliers and release capacity at existing sites for other products.

At Kakinada, Unit 3 had six blocks operational and two under construction in FY26. The company has also discussed upcoming generic product launches, although it did not identify individual molecules or launch dates. Custom Synthesis: From Customer Engagement to Commercial Volumes Divi’s custom synthesis operations cover advanced intermediates and APIs for global pharmaceutical innovators. Capabilities include high-potency compounds, high-energy reactions, registered starting materials, complex chemistry and peptide synthesis.

Its FY26 annual report confirms relationships with 12 of the world's 20 largest pharmaceutical companies. During the year, customer engagement included requests for proposals, site visits and programmes progressing towards commercial manufacturing. Three major capital expenditure programmes backed by long-term supply commitments were under way, with some expected to move towards commercial volumes over the following 12–24 months, subject to customer approvals and regulatory clearances.

The company also established a Peptide Centre of Excellence and expanded solid-phase and liquid-phase peptide synthesis, flow chemistry and biocatalysis. Q1FY27 Performance: Strong Consolidated Growth, Limited Segment Visibility Divi’s reported consolidated revenue from operations was ₹3,080 crore for Q1FY27, up 27.8% year on year and approximately 8.8% sequentially. Profit after tax (PAT) increased 65.5% year on year to ₹902 crore and approximately 20% sequentially.

Custom synthesis contributed around 60% of standalone revenue during Q1FY27, while generic APIs contributed approximately 40%. The company invested more than ₹1,500 crore across its manufacturing network in FY26. Why Europe’s ₹6,311 Crore Share Drives Divi’s Currency and Trade Risk Divi’s FY26 geographical sales were concentrated in Europe, which contributed approximately ₹6,311 crore. North America accounted for ₹1,360 crore, India ₹1,147 crore, Asia ₹1,079 crore and the rest of the world ₹479 crore.

This geographical mix makes overseas demand, regulatory requirements, logistics and trade-policy changes relevant to the business. Divi’s Is Already Closing In on the Brokerage Target Source: Screener.in; Stock Price as on 15th October 2026 Divi’s Laboratories rose more than 43% over six months, while its 52-week return stood at 37.2%. The company has a P/E ratio of 80.4. JPMorgan reiterated its Buy rating on 4 August 2026, retaining a target price of ₹9,100.

At the 15 October 2026 closing price of ₹9,030, the target implied only slight upside. The Chemistry Behind the Opportunity: Why Commercial Production Is Harder Than It Looks Key obstacles include strict quality standards for pharmaceutical ingredients. Even small variations can require additional testing or changes to the manufacturing process. If a company cannot consistently meet the required standards, it may face delayed deliveries, regulatory scrutiny or additional costs to correct the problem.

For businesses supplying global pharmaceutical companies, maintaining consistent quality is essential to securing repeat orders and retaining customer relationships. Environmental compliance also affects profitability. Producing drug ingredients can involve significant quantities of chemicals, solvents and industrial waste. Companies must invest in waste treatment, safe disposal and pollution-control systems.

These expenses add to operating costs, while stricter environmental requirements can lead to further investment. A manufacturing plant may have substantial production capacity, but its financial performance will depend on how efficiently it operates and how much it costs to meet quality and environmental standards. The Real Test: Which Business Can Turn Chemistry Into Cash? Before adding any of these companies to your watchlist, ask one question: what evidence would convince you that its business can deliver more than the market already expects?

For Aurobindo Pharma, track whether API growth broadens beyond its stronger product category. For Laurus Labs, watch whether its expanding CDMO pipeline translates into commercial orders and supports returns on recent investments. For Divi’s Laboratories, look for progress in customer-backed projects and the start of commercial supplies. The bigger opportunity is not necessarily the company with the fastest-growing segment.

It is the one that can convert customer demand into repeat orders, maintain production quality and generate adequate returns on the capital invested. Compare these signals with each company’s valuation before deciding whether the potential justifies the risk. Keep all three on your radar, but let reported business progress, rather than past share-price performance, guide your next move. It may be a good idea to add these stocks to your watchlist and keep track to see how they perform in time to come.

Disclaimer: Note: We have relied on data from www.Screener.in throughout this article. Only in cases where the data was not available, have we used an alternate, but widely used and accepted source of information. The purpose of this article is only to share interesting charts, data points and thought-provoking opinions. It is NOT a recommendation. If you wish to consider an investment, you are strongly advised to consult your advisor.

This article is strictly for educative purposes only. Rishabh Sinha is a seasoned financial content creator with over 10 years of experience in BFSI domain. His portfolio spans over 20 of India’s most trusted financial brands. Rishabh brings depth, structure, and a reader-first approach to every piece he crafts. Disclosure: The writer and his dependents do not hold the stocks discussed in this article.

The website managers, its employee(s), and contributors/writers/authors of articles have or may have an outstanding buy or sell position or holding in the securities, options on securities or other related investments of issuers and/or companies discussed therein. The content of the articles and the interpretation of data are solely the personal views of the contributors/ writers Investors must make their own investment decisions based on their specific objectives, resources and only after consulting such independent advisors as may be necessary.